细胞程序性死亡蛋白1配体1(PDL1)等多因子检测试剂盒(流式荧光发光法)
Multiplex Assay Kit for Programmed Cell Death Protein 1 Ligand 1 (PDL1) ,etc. by FLIA (Flow Luminescence Immunoassay)
CD274; PDCD1LG1; B7-H; B7H1; PD-L1; PDCD1L1; PDCD1-LG1; Programed Death Ligand 1
（注：单次混测多因子不超过8个指标 ）
- 编号LMA788Hu
- 物种Homo sapiens (Human，人) 相同的名称，不同的物种。
- 实验方法双抗夹心
- 反应时长3.5h
- 检测范围0.01-10ng/mL
- 灵敏度最小可检测剂量小于等于0.003 ng/mL.
- 样本类型serum, plasma, tissue homogenates and other biological fluids.
- 下载 英文说明书 中文说明书
- 规格 8指标数 7指标数 6指标数 5指标数 4指标数 3指标数 2指标数1指标数
- 价格 ¥ 2359 ¥ 2449 ¥ 2586 ¥ 2767 ¥ 2948 ¥ 3221 ¥ 3629 ¥ 4536 添加到价格计算器 计算器
- 欲了解实际交易价格和更多情况，请与当地经销商联系!
-
产品包装(模拟)
-
产品包装(模拟)
-
通过ISO 9001、ISO 13485质量体系认证
特异性
本试剂盒用于检测细胞程序性死亡蛋白1配体1(PDL1)等多因子检测试剂盒(流式荧光发光法)，经检测与其它相似物质无明显交叉反应。
由于受到技术及样本来源的限制，不可能完成对所有相关或相似物质交叉反应检测，因此本试剂盒有可能与未经检测的其它物质有交叉反应。
回收率
分别于定值血清及血浆样本中加入一定量的细胞程序性死亡蛋白1配体1(PDL1)等多因子检测试剂盒(流式荧光发光法)（加标样品），重复测定并计算其均值，回收率为测定值与理论值的比率。
| 样本 | 回收率范围(%) | 平均回收率(%) |
| serum(n=5) | 87-101 | 92 |
| EDTA plasma(n=5) | 91-99 | 95 |
| heparin plasma(n=5) | 80-90 | 86 |
精密度
精密度用样品测定值的变异系数CV表示。CV(%) = SD/mean×100
批内差：取同批次试剂盒对低、中、高值定值样本进行定量检测,每份样本连续测定20 次，分别计算不同浓度样本的平均值及SD值。
批间差：选取3个不同批次的试剂盒分别对低、中、高值定值样本进行定量测定，每个样本使用同一试剂盒重复测定8次，分别计算不同浓度样本的平均值及SD值。
批内差： CV<10%
批间差： CV<12%
线性
在定值血清及血浆样本内加入适量的细胞程序性死亡蛋白1配体1(PDL1)等多因子检测试剂盒(流式荧光发光法)，并倍比稀释成1:2，1:4，1:8，1:16的待测样本，线性范围即为稀释后样本中细胞程序性死亡蛋白1配体1(PDL1)等多因子检测试剂盒(流式荧光发光法)含量的测定值与理论值的比率。
| 样本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 86-99% | 85-99% | 93-101% | 78-104% |
| EDTA plasma(n=5) | 82-97% | 98-105% | 89-98% | 85-103% |
| heparin plasma(n=5) | 78-95% | 90-99% | 90-101% | 98-105% |
稳定性
经测定，试剂盒在有效期内按推荐温度保存，其活性降低率小于5%。
为减小外部因素对试剂盒破坏前后检测值的影响，实验室的环境条件需尽量保持一致，尤其是实验室内温度、湿度及温育条件。其次由同一实验员来进行操作可减少人为误差。
实验流程
1. 实验前标准品、试剂及样本准备；
2. 加样（标准品、样本、磁珠）标准品或样本100μL及磁珠10μL，
37°C酶标板振荡器孵育90分钟；
3. 磁吸甩干，加检测溶液A100μL，37°C酶标板振荡器孵育60分钟；
4. 磁吸洗板3次；
5. 加检测溶液B100μL，37°C振动孵育30分钟；
6. 磁吸洗板3次；
7. 加鞘液100μL，旋涡震荡2分钟后读数。
实验原理
将细胞程序性死亡蛋白1配体1(PDL1)等多因子检测试剂盒(流式荧光发光法)抗体包被于磁珠，制成固相载体，向微孔中分别加入标准品或标本以及磁珠，其中的细胞程序性死亡蛋白1配体1(PDL1)等多因子检测试剂盒(流式荧光发光法)与连接于固相载体上的抗体结合，然后加入生物素化的细胞程序性死亡蛋白1配体1(PDL1)等多因子检测试剂盒(流式荧光发光法)抗体，将未结合的生物素化抗体洗净后，加入PE标记的亲和素，再次彻底洗涤后即可上机读数。MFI值和样品中的细胞程序性死亡蛋白1配体1(PDL1)等多因子检测试剂盒(流式荧光发光法)呈正相关。
赠品
增值服务
相关产品
| 编号 | 适用物种：Homo sapiens (Human，人) | 应用(仅供研究使用，不用于临床诊断！) |
| RPA788Hu02 | 细胞程序性死亡蛋白1配体1(PDL1)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPA788Hu01 | 细胞程序性死亡蛋白1配体1(PDL1)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| APA788Hu61 | 细胞程序性死亡蛋白1配体1(PDL1)活性蛋白 | Cell culture; Activity Assays. |
| EPA788Hu61 | 细胞程序性死亡蛋白1配体1(PDL1)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAA788Hu01 | 细胞程序性死亡蛋白1配体1(PDL1)多克隆抗体 | WB,ICC/IF |
| FAA788Hu01 | 抗细胞程序性死亡蛋白1配体1(PDL1)多克隆抗体 | Flow cytometry. |
| FAA788Hu41 | 抗细胞程序性死亡蛋白1配体1(PDL1)多克隆抗体(藻红素标记) | Flow cytometry. |
| FAA788Hu51 | 抗细胞程序性死亡蛋白1配体1(PDL1)多克隆抗体(别藻蓝蛋白标记) | Flow cytometry. |
| FAA788Hu81 | 抗细胞程序性死亡蛋白1配体1(PDL1)多克隆抗体(异硫氰酸荧光素标记) | Flow cytometry. |
| MAA788Hu28 | 细胞程序性死亡蛋白1配体1(PDL1)单克隆抗体 | WB; IHC; ICC; IP. |
| MAA788Hu22 | 细胞程序性死亡蛋白1配体1(PDL1)单克隆抗体 | WB; IHC; ICC; IP. |
| RAA788Hu22 | 细胞程序性死亡蛋白1配体1(PDL1)重组抗体 | WB; IF; ICC; IHC; IP; FCM. |
| MAA788Hu21 | 细胞程序性死亡蛋白1配体1(PDL1)单克隆抗体 | WB; IHC; ICC; IP. |
| MAA788Hu23 | 细胞程序性死亡蛋白1配体1(PDL1)单克隆抗体 | WB; IHC; ICC; IP. |
| MAA788Hu24 | 细胞程序性死亡蛋白1配体1(PDL1)单克隆抗体 | WB; IHC; ICC; IP. |
| MAA788Hu25 | 细胞程序性死亡蛋白1配体1(PDL1)单克隆抗体 | WB; IHC; ICC; IP. |
| MAA788Hu27 | 细胞程序性死亡蛋白1配体1(PDL1)单克隆抗体 | WB; IHC; ICC; IP. |
| MAA788Hu29 | 细胞程序性死亡蛋白1配体1(PDL1)单克隆抗体 | WB; IHC; ICC; IP. |
| MAA788Hu26 | 细胞程序性死亡蛋白1配体1(PDL1)单克隆抗体 | WB; IHC; ICC; IP. |
| RAA788Hu21 | 细胞程序性死亡蛋白1配体1(PDL1)重组抗体 | WB; IF; ICC; IHC; IP; FCM. |
| LAA788Hu72 | 细胞程序性死亡蛋白1配体1(PDL1)单克隆抗体(生物素标记) | WB; IHC; ICC. |
| FAA788Hu82 | 抗细胞程序性死亡蛋白1配体1(PDL1)单克隆抗体(异硫氰酸荧光素标记) | Flow cytometry. |
| WEA788Hu | 细胞程序性死亡蛋白1配体1(PDL1)检测试剂盒(酶联免疫吸附试验法,宽范围) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| SEA788Hu | 细胞程序性死亡蛋白1配体1(PDL1)检测试剂盒(酶联免疫吸附试验法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| SCA788Hu | 细胞程序性死亡蛋白1配体1(PDL1)检测试剂盒(化学发光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
| LMA788Hu | 细胞程序性死亡蛋白1配体1(PDL1)等多因子检测试剂盒(流式荧光发光法) | FLIA Kit for Antigen Detection. |
| PSA788Hu01 | 细胞程序性死亡蛋白1配体1(PDL1)抗体对 | ELISA; CLIA; ELISPOT; Luminex; Immunochromatography and other Immunoassays. |
| KSA788Hu01 | 细胞程序性死亡蛋白1配体1(PDL1)检测试剂盒DIY材料(酶联免疫吸附试验法) | Main materials for "Do It (ELISA Kit) Yourself". |
参考文献
| 杂志 | 参考文献 |
| Chinese Journal of Cancer | Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications [NCBI: PMC3937742] |
| Leukemia.? | High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. [Pubmed:24732592] |
| Diabetes?Metab Res Rev. | PD‐L1 gene polymorphisms and low serum level of PD‐L1 protein are associated to type 1 diabetes in Chile [Pubmed:24816853] |
| Lancet Haematol | Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study [PubMed: 26686046] |
| Eur J Cancer. | High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis. [Pubmed:27039170] |
| Journal of Cancer Research and Clinical Oncology | Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer [article:10.1007] |
| Journal of Hematology & Oncology | PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma [pubmed:27737703] |
| Lung Cancer. | High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer. [pubmed:28212990] |
| Oncotarget | Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predictssurvival in advanced biliary tract cancer patients treated with palliative chemotherapy. [pubmed:27780932] |
| Oncotarget | High post-treatment serum levels of soluble programmed cell death ligand 1 predict earlyrelapse and poor prognosis in extranodal NK/T cell lymphoma patients. [pubmed:27105512] |
| Oncotarget. | Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma [pubmed:27566569] |
| Cancer Immunol Immunother. | Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy. [pubmed:28349165] |
| Leukemia | Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients [leu2016385a] |
| Medicine | Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy. [pubmed:28207525] |
| Allergology International | Inverse correlation of soluble programmed cell death-1 ligand-1 (sPD-L1) with eosinophil count and clinical severity in allergic rhinitis patients [pubmed:27617656] |
| Medicine | Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy [PMC5319514] |
| American Journal of Respiratory and Critical Care Medicine | Soluble Programed Death Receptor 1 Ligand (sPD-L1) in Pleural Fluid of Patients with Malignant Pleural Mesothelioma (MPM) [Pdf:10.1164] |
| Clinical Lung Cancer | Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non–Small-cell Lung Cancer [Pubmed:29859759] |
| Journal of Rheumatology | Increased levels of soluble programmed death ligand 1 associate with malignancy in patients with dermatomyositis [Pubmed:29419471] |
| Translational Oncology | High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma [Pubmed:29698935] |
| Immunology Letters | Increased levels of soluble co-stimulatory molecule PD-L1 (B7-H1) in the plasma of viraemic HIV-1+ individuals [Pubmed: 30236481] |
| Journal of Cancer Research and Clinical Oncology | Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma [Pubmed: 30267213] |
| Annals of Surgical Oncology | Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between … [Pubmed: 30565045] |
| American Journal of Reproductive Immunology | Identification of programmed cell death 1 and its ligand in the testicular tissue of mice [Pubmed: 30578744] |
| PLoS One | Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated … [Pubmed: 30807610] |
| Endocrine Connections | Elevated levels of soluble PD-L1 are associated with reduced recurrence in papillary thyroid cancer [Pubmed: 31252406] |
| Scientific Reports | Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer [Pubmed: 31366979] |
| Critical Reviews in Oncology / Hematology | The Clinical Significance of Soluble PD-1 and PD-L1 in Lung Cancer [Pubmed: 31675543] |
| PLoS One | Clinical implications of APOBEC3A and 3B expression in patients with breast cancer [Pubmed: 32176735] |
| Cancers | Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study [Pubmed: 32085544] |
| Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma [Pubmed: 32054467] | |
| LIVER INTERNATIONAL | The prognostic role of soluble transforming growth factor‐β and its correlation with soluble programmed death‐ligand 1 in biliary tract cancer [Pubmed: 32780918] |
| CANCER IMMUNOLOGY IMMUNOTHERAPY | Prognostic impacts of tumoral expression and serum levels of PD-L1 and CTLA-4 in colorectal cancer patients [Pubmed: 32577816] |
| Soluble PD-L1: a potential immune marker for HIV-1 infection and virological failure [Pubmed: 32443313] | |
| Cancer Immunol Immunother | The clinical implication of soluble PD-L1 (sPD-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyte [33688997] |
| Acta Biochim Biophys Sin | Prognostic prospect of soluble programmed cell death ligand-1 (sPD-L1) in cancer management [34180502] |
| EMBO J | Microglial PD‐1 stimulation by astrocytic PD‐L1 suppresses neuroinflammation and Alzheimer's disease pathology [34825707] |
| Mol Pharm | A Novel Small Cyclic Peptide-Based 68Ga-Radiotracer for Positron Emission Tomography Imaging of PD-L1 Expression in Tumors [34910492] |
| Mol Hum Reprod | Macrophage Associated Immune Checkpoint CD47 Blocking Ameliorates Endometriosis [Pubmed:35404426] |
| Journal of Nanobiotechnology | Microbial hydrogen “manufactory” for enhanced gas therapy and self-activated immunotherapy via reduced immune escape [Pubmed:35705974] |
| Medicina | Assessment of the RANTES Level Correlation and Selected Inflammatory and Pro-Angiogenic Molecules Evaluation of Their Influence on CRC Clinical Features: A … [Pubmed:35208526] |
留言咨询